Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) remain major clinical challenges, with high mortality rates and increasing antimicrobial resistance complicating treatment decisions. 1,2 The rise of ESBL- and AmpC-producing Enterobacteriaceae further narrows viable therapeutic options, placing emphasis on agents that deliver both broad-spectrum activity and reliable pharmacokinetic performance . 3,4 Explore our infographic to understand how the Cefepime–Enmetazobactam combination is positioned within this evolving landscape.
It highlights key evidence demonstrating its activity against ESBL/AmpC-producing pathogens, prevalence patterns of HAP in India, intrapulmonary pharmacokinetics, and its regimen achieving pharmacodynamic targets consistently at recommended dosing intervals ⁴,⁵. This concise visual summary equips clinicians with relevant, data-driven…
